Copland M, Jorgensen HG, Holyoake TL. Evolving molecular therapy for chronic myeloid leukaemia-are we on target? Hematology [Internet]. 2005 [cited 01/09/2020]; 10:349–359. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/10245330500234195

Fruhwirth GO, Kneilling M, de Vries IJM et al. The potential of in vivo imaging for optimization of molecular and cellular anti-cancer immunotherapies. Mol Imaging Biol[Internet]. 2018 [cited 01/09/2020]. Disponible en: https://doi.org/10.1007/s11307-018-1254-3.

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism [Internet]. 2016[cited 01/09/2020]; 23(1):27-47. Disponible en: https://doi:10.1016/j.cmet.2015.12.006.

Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res[Internet]. 2015[cited 01/09/2020]; 75:544–553.Disponible en: https://doi.org/10.1158/0008-5472.CAN-14-2211

Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies. Front Oncol[Internet]. 2020[cited 01/09/2020]; 10:589508.Disponible en:https://doi:10.3389/fonc.2020.589508.

Catenacci DVT. Next-generation clinical trials: Novel strategies toaddress the challenge of tumormolecular heterogeneity. Mol Oncol[Internet].2015[cited 01/09/2020]; 9:967–996. Disponible en:https://doi:10.1016/j.molonc.2014.09.011.